WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology…

Mpox spreads across 11 districts in W/Region

By Juliet Aguiar DUGBARTEY, Takoradi The Western Regional Health Directorate has confirmed 97 Mpox cases out of 387 suspected infections reported between January and July 12, 2025. A situation report made available to the Business and Financial Times (B&FT) indicated that all 387 suspected cases were tested. Of these, 260 returned negative results, while results for 53 cases are still pending. So far, 460 contacts linked to the suspected cases h…

Mpox Antiviral Drug Trial Advances as WHO Extends Global Emergency

The World Health Organization (WHO) has reaffirmed the global Public Health Emergency of International Concern (PHEIC) for mpox, amid rising case counts, evolving viral strains, and significant operational and funding [...] Read the rest of Mpox Antiviral Clinical Trial Advances as WHO Extends Global Emergency at Global Biodefense

NanoViricides, Inc. Advances MPox Treatment Amid WHO’s Extended Global Health Emergency

NanoViricides, Inc. (NYSE American: NNVC), a leader in the development of host-mimetic nanomedicine, has reaffirmed its commitment to combating the MPox virus following the World Health Organization’s decision to extend the Public Health Emergency of International Concern (PHEIC). The company’s focus is on NV-387, a broad-spectrum antiviral drug that has successfully completed Phase I trials, demonstrating a strong safety profile, and is now mov…